Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Novavax almost doubled ...
Sanofi on Friday said it had reached a deal worth up to $1.2 billion to sell Novavax’s Covid shot as well as to try to ...
Novavax shares (NVAX) surged after the vaccine maker said it had struck a licensing deal worth up to $1.4 billion with Sanofi ...
Shah Capital, a top shareholder of Novavax (NASDAQ:NVAX), has withdrawn its proxy campaign against the company days after the ...
The deal also entitles Novavax to an upfront ... as well as royalties. Sanofi, one of the world's largest vaccine makers, will gain a license to co-sell Novavax's vaccine in most countries and ...
Novavax shares jumped 50% on Monday following its recent licensing deal with Sanofi, as meme stocks are making a 2021-style ...
Hedge fund Shah Capital said on Monday it would withdraw its campaign against the re-election of three directors on Novavax's ...
Novavax (NASDAQ:NVAX) shares hit a 52-week high on Friday as the COVID-19 vaccine maker removed its going-concern notice with ...
Sanofi will also have a non-exclusive license to use Novavax's Matrix-M adjuvant in other vaccine products. Novavax will ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Novavax (NASDAQ:NVAX) stock has more than doubled today and is up more than ...
Novavax on Friday said it had struck a licensing deal worth at least $1.2 billion with Sanofi, opens new tab for its COVID-19 vaccine in exchange for a stake that valued the U.S. biotech firm at ...